

MEET THE EXPERT SESSION


Impact of treatment choices on live birth and pregnancy rates




Join esteemed speakers **Prof. Philippe Lehert** and **Dr. Christos Venetis** to:

May 5th 2021 5–6 pm SGT

 Reflect on the what previous studies have highlighted around the role of r-hLH in ART

 Assess the effectiveness of r-hLH supplementation on cumulative live birth rate in poor ovarian responders, within a real-world setting

 Discuss the differences in outcomes from observational studies and randomized controlled trials

 Evaluate the safety and efficacy of biosimilar follitropin alfa compared with the reference product

5:00–5:05 pm Welcome and introduction



Thomas D'Hooghe

5:05–5:25 pm

Effect of recombinant LH supplementation on cumulative live birth rate compared with FSH alone in poor ovarian responders: a large, real world study?



Philippe Lehert

5:25–5:30 pm

Q&A discussion

5:30–5:50 pm

Biosimilar recombinant follitropin alfa preparations versus the reference product in couples undergoing assisted reproductive technology treatment: A systematic review and meta-analysis



Christos Venetis

5:50–6:00 pm

Q&A discussion

For Healthcare Professionals only.

We look forward to seeing you on the ASPIRE platform on the 5th May at 5.00 pm SGT!

MERCK

Statements of fact and opinions expressed are those of the third party speakers individually. Do not share this invitation with anyone who is not a healthcare professional.

Discussion concerning drugs, treatments, doses and procedures are intended for an international audience and may reflect procedures and/or approved labelling in countries other than Singapore.

SG-NONF-00027 April 2021